Elliot Goldstein, CEO of ProMIS Neurosciences, on moving the Alzheimer's goalposts

27 July 2016

Treating the symptoms of Alzheimer’s is akin to painting the lines on a bridge that is collapsing, says Elliot Goldstein, chief executive of ProMIS Neurosciences (TSE: PMN), as his company prepares to present some of its research at the Alzheimer’s Association International Conference (AAIC).

The Canada-based biotech’s main focus is on developing precision therapeutics targeting strains of misfolded, neurotoxic prion forms of Amyloid beta (Aβ) and strains of the protein tau, which it sees as the root cause of Alzheimer’s, and Dr Goldstein has an end goal in mind.

“With Alzheimer's you can lose billions of neurons over 10 to 15 years,” he says. “The holy grail is to find the bad actor protein, diagnose which strain a patient has and pertinently administer vaccine products to knock it out before there are any symptoms."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK